Loading data for PCVX — first visit, this takes a few seconds.
Vaxcyte, Inc. (PCVX)
NasdaqGS: PCVX
· 即時價格 · USD
60.36
-0.80 (-1.31%)
收盤價： Sep 08, 2026, 8:00 PM
60.45
+0.15%
盤前: 7:32 AM
股價、關鍵數字和最新消息，都在這一頁。
Vaxcyte, Inc.（PCVX）股價、分析與資料
無可用資料
| 買價 | 43.42 |
| 市值 | 8.98B |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -1.06B |
| 1.22 | |
| -7.63 | |
| n/a | |
| -8.36 | |
| P/B (ttm) | 3.17 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 3, 2026 |
| 賣價 | 76.16 |
| 成交量 | 1,023,290 |
| 20 日平均成交量 | 1,300,429 |
| 開盤價 | 60.25 |
| 前收盤價 | 61.16 |
| 當日區間 | 59.22 - 61.03 |
| 52 週範圍 | 30.81 - 65.00 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of...
完整的公司簡介財報驚奇
Vaxcyte 已於 Aug 5, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -1.97 超出預期 0.13, 年增 -61.48% 下滑.
第 1 頁，共 2 頁